Pairwise learning to rank by neural networks revisited:reconstruction, theoretical analysis and practical performance

We reevaluate the pairwise learning to rank approach based on neural nets, called RankNet, and present a theoretical analysis of its architecture. We show mathematically that the model can, under certain conditions, learn reflexive, antisymmetric, and transitive relations, enabling simplified training and improved performance. Experimental results on the LETOR MSLR-WEB10K, MQ2007 and MQ2008 datasets show that the model outperforms numerous state-of-the-art methods (including a listwise approach), while being inherently simpler in structure and using a pairwise approach only

Pairwise learning to rank by neural networks revisited:reconstruction, theoretical analysis and practical performance

We present a pairwise learning to rank approach based on a neural net, called DirectRanker, that generalizes the RankNet architecture. We show mathematically that our model is reflexive, antisymmetric, and transitive allowing for simplified training and improved performance. Experimental results on the LETOR MSLR-WEB10K, MQ2007 and MQ2008 datasets show that our model outperforms numerous state-of-the-art methods, while being inherently simpler in structure and using a pairwise approach only.Comment: 16 pages, 8 figure

Shining Light on the Scotogenic Model: Interplay of Colliders and Cosmology

In the framework of the scotogenic model, which features radiative generation of neutrino masses, we explore light dark matter scenario. Throughout the paper we chiefly focus on keV-scale dark matter which can be produced either via freeze-in through the decays of the new scalars, or from the decays of next-to-lightest fermionic particle in the spectrum, which is produced through freeze-out. The latter mechanism is required to be suppressed as it typically produces a hot dark matter component. Constraints from BBN are also considered and in combination with the former production mechanism they impose the dark matter to be light. For this scenario we consider signatures at High Luminosity LHC and proposed future hadron and lepton colliders, namely FCC-hh and CLIC, focusing on searches with two leptons and missing energy as a final state. While a potential discovery at High Luminosity LHC is in tension with limits from cosmology, the situation greatly improves for future colliders.Comment: 28 pages, 11 figures, matches published versio

The 2015 Annual Meeting of SETAC German Language Branch in Zurich (7-10 September, 2015): ecotoxicology and environmental chemistry-from research to application

This report provides a brief review of the 20th annual meeting of the German Language Branch of the Society of Environmental Toxicology and Chemistry (SETAC GLB) held from September 7th to 10th 2015 at ETH (Swiss Technical University) in Zurich, Switzerland. The event was chaired by Inge Werner, Director of the Swiss Centre for Applied Ecotoxicology (Ecotox Centre) Eawag-EPFL, and organized by a team from Ecotox Centre, Eawag, Federal Office of the Environment, Federal Office of Agriculture, and Mesocosm GmbH (Germany). Over 200 delegates from academia, public agencies and private industry of Germany, Switzerland and Austria attended and discussed the current state of science and its application presented in 75 talks and 83 posters. In addition, three invited keynote speakers provided new insights into scientific knowledge ‘brokering’, and—as it was the International Year of Soil—the important role of healthy soil ecosystems. Awards were presented to young scientists for best oral and poster presentations, and for best 2014 master and doctoral theses. Program and abstracts of the meeting (mostly in German) are provided as Additional file 1

An overview of the reproductive cycle of cultured specimens of a potential candidate for Mediterranean aquaculture, Umbrina cirrosa

The shi drum (Umbrina cirrosa), belonging to the Sciaenidae family of fish (Nelson et al., 2016) has attracted attention as it is an excellent diversification species in Mediterranean aquaculture to combat the low prices of the most cultured species due to the appearance of new producing countries in the Mediterranean area. In this manuscript we describe for the first time the reproductive cycle of captive shi drum specimens that are able to spontaneously spawn in captivity. Our data show that spermatogenesis started in one year old shi drum spe- cimens, although the fish were not mature enough to complete the reproductive cycle. Thus, three year old specimens showed multiple spawns with around 65% of the eggs fertilized. In mature males, levels of 11-ke- totestosterone (11KT), testosterone (T) and progesterone (P) were detected in serum and gonad, while 17β- estradiol (E2) was only detected in gonad. Testicular levels of E2 and P suggest that these hormones might have a role in spawning and in the subsequent spermatogonial proliferation. In mature females, however, P and E2 were detected in serum and gonad, while T and 11KT were only detected in gonad. The pattern shown by P in the ovary indicates a link between this hormone and ovarian renewal and a delay in vitellogenesis, which would explain why the vitellogenic stage of shi drum is quite short. The level of T and 11KT in the ovary suggests a role in oocyte maturation and spawning. The differences observed between sexes in the prevalence of some infection and the important economic losses produced by some vertically transmitted pathogens; have increase the at- tention to the interactions between the immune and reproductive systems. In this study we observed differences between sexes in the protease and bactericide activity levels. Thus, this manuscript represents the most complete overview to date of the shi drum reproductive cycle.Versión del editor2,04

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial

Background: Liraglutide 3·0 mg was shown to reduce bodyweight and improve glucose metabolism after the 56-week period of this trial, one of four trials in the SCALE programme. In the 3-year assessment of the SCALE Obesity and Prediabetes trial we aimed to evaluate the proportion of individuals with prediabetes who were diagnosed with type 2 diabetes. Methods: In this randomised, double-blind, placebo-controlled trial, adults with prediabetes and a body-mass index of at least 30 kg/m2, or at least 27 kg/m2 with comorbidities, were randomised 2:1, using a telephone or web-based system, to once-daily subcutaneous liraglutide 3·0 mg or matched placebo, as an adjunct to a reduced-calorie diet and increased physical activity. Time to diabetes onset by 160 weeks was the primary outcome, evaluated in all randomised treated individuals with at least one post-baseline assessment. The trial was conducted at 191 clinical research sites in 27 countries and is registered with ClinicalTrials.gov, number NCT01272219. Findings: The study ran between June 1, 2011, and March 2, 2015. We randomly assigned 2254 patients to receive liraglutide (n=1505) or placebo (n=749). 1128 (50%) participants completed the study up to week 160, after withdrawal of 714 (47%) participants in the liraglutide group and 412 (55%) participants in the placebo group. By week 160, 26 (2%) of 1472 individuals in the liraglutide group versus 46 (6%) of 738 in the placebo group were diagnosed with diabetes while on treatment. The mean time from randomisation to diagnosis was 99 (SD 47) weeks for the 26 individuals in the liraglutide group versus 87 (47) weeks for the 46 individuals in the placebo group. Taking the different diagnosis frequencies between the treatment groups into account, the time to onset of diabetes over 160 weeks among all randomised individuals was 2·7 times longer with liraglutide than with placebo (95% CI 1·9 to 3·9, p<0·0001), corresponding with a hazard ratio of 0·21 (95% CI 0·13–0·34). Liraglutide induced greater weight loss than placebo at week 160 (–6·1 [SD 7·3] vs −1·9% [6·3]; estimated treatment difference −4·3%, 95% CI −4·9 to −3·7, p<0·0001). Serious adverse events were reported by 227 (15%) of 1501 randomised treated individuals in the liraglutide group versus 96 (13%) of 747 individuals in the placebo group. Interpretation: In this trial, we provide results for 3 years of treatment, with the limitation that withdrawn individuals were not followed up after discontinuation. Liraglutide 3·0 mg might provide health benefits in terms of reduced risk of diabetes in individuals with obesity and prediabetes. Funding: Novo Nordisk, Denmark

Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial

Background: Semaglutide, a GLP-1 receptor agonist, reduces the risk of major adverse cardiovascular events (MACE) in people with overweight or obesity, but the effects of this drug on outcomes in patients with atherosclerotic cardiovascular disease and heart failure are unknown. We report a prespecified analysis of the effect of once-weekly subcutaneous semaglutide 2·4 mg on ischaemic and heart failure cardiovascular outcomes. We aimed to investigate if semaglutide was beneficial in patients with atherosclerotic cardiovascular disease with a history of heart failure compared with placebo; if there was a difference in outcome in patients designated as having heart failure with preserved ejection fraction compared with heart failure with reduced ejection fraction; and if the efficacy and safety of semaglutide in patients with heart failure was related to baseline characteristics or subtype of heart failure. Methods: The SELECT trial was a randomised, double-blind, multicentre, placebo-controlled, event-driven phase 3 trial in 41 countries. Adults aged 45 years and older, with a BMI of 27 kg/m2 or greater and established cardiovascular disease were eligible for the study. Patients were randomly assigned (1:1) with a block size of four using an interactive web response system in a double-blind manner to escalating doses of once-weekly subcutaneous semaglutide over 16 weeks to a target dose of 2·4 mg, or placebo. In a prespecified analysis, we examined the effect of semaglutide compared with placebo in patients with and without a history of heart failure at enrolment, subclassified as heart failure with preserved ejection fraction, heart failure with reduced ejection fraction, or unclassified heart failure. Endpoints comprised MACE (a composite of non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death); a composite heart failure outcome (cardiovascular death or hospitalisation or urgent hospital visit for heart failure); cardiovascular death; and all-cause death. The study is registered with ClinicalTrials.gov, NCT03574597. Findings: Between Oct 31, 2018, and March 31, 2021, 17 604 patients with a mean age of 61·6 years (SD 8·9) and a mean BMI of 33·4 kg/m2 (5·0) were randomly assigned to receive semaglutide (8803 [50·0%] patients) or placebo (8801 [50·0%] patients). 4286 (24·3%) of 17 604 patients had a history of investigator-defined heart failure at enrolment: 2273 (53·0%) of 4286 patients had heart failure with preserved ejection fraction, 1347 (31·4%) had heart failure with reduced ejection fraction, and 666 (15·5%) had unclassified heart failure. Baseline characteristics were similar between patients with and without heart failure. Patients with heart failure had a higher incidence of clinical events. Semaglutide improved all outcome measures in patients with heart failure at random assignment compared with those without heart failure (hazard ratio [HR] 0·72, 95% CI 0·60-0·87 for MACE; 0·79, 0·64-0·98 for the heart failure composite endpoint; 0·76, 0·59-0·97 for cardiovascular death; and 0·81, 0·66-1·00 for all-cause death; all pinteraction>0·19). Treatment with semaglutide resulted in improved outcomes in both the heart failure with reduced ejection fraction (HR 0·65, 95% CI 0·49-0·87 for MACE; 0·79, 0·58-1·08 for the composite heart failure endpoint) and heart failure with preserved ejection fraction groups (0·69, 0·51-0·91 for MACE; 0·75, 0·52-1·07 for the composite heart failure endpoint), although patients with heart failure with reduced ejection fraction had higher absolute event rates than those with heart failure with preserved ejection fraction. For MACE and the heart failure composite, there were no significant differences in benefits across baseline age, sex, BMI, New York Heart Association status, and diuretic use. Serious adverse events were less frequent with semaglutide versus placebo, regardless of heart failure subtype. Interpretation: In patients with atherosclerotic cardiovascular diease and overweight or obesity, treatment with semaglutide 2·4 mg reduced MACE and composite heart failure endpoints compared with placebo in those with and without clinical heart failure, regardless of heart failure subtype. Our findings could facilitate prescribing and result in improved clinical outcomes for this patient group. Funding: Novo Nordisk